Menu di pagina
- IRE Research and Technology
- IRE Competitive Grants
- PerfeTTO
- INNOVA
- Immune Metabolism Dysregulation and Efficacy of Anti-PD-1/PD-L1 Agents in Non-Small Cell Lung Cancer (NSCLC)
- Artificial Intelligence and Machine Learning Based Risk Prediction Model for Improving Endometrial Cancer Clinical Management
- Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation after robot-assisted surgical treatment of genitourinary cancers
- Deciphering KEAPness for Improved Immunotherapy Prediction and Treatment
- MiRNA-based therapeutic approach to fight triple negative breast cancer
- Beyond the creation of a living biobank: dissecting the transcriptomic landscape of Gastro-entero-pancreatic neuroendocrine neoplasms
- Multidimensional assessment of virus-associated head and neck cancer patients for the discovery of predictive biomarkers to guide clinical intervention
- TArgeting drug resistant melanoma with miCroRNAs delivered by Lipid NanoparTICles (TACTIC)
- Addressing liver fibrosis prevention and treatment: an unbiased query on the hepatic microenvironment with a perspective targeting of the pro-fibrotic kinase HIPK2
- Analyses of HPV and host body fluid biomarkers as non-invasive strategy for detection of head and neck cancer relapse
- Deciphering Biology of R/R DLBCL Subtypes: miRNA Biomarkers for Optimizing Treatment and Survival
- Clinically approved drugs targeting pyruvate kinase M2: a drug repurposing pathway to move forward the treatment of glioblastoma
- Developing a Biobank Network Among Major Sarcoma Treatment Centers to Improve Biomedical Research
- Identification and Validation of Prognostic and Predictive Biomarkers, Including E3 Ubiquitin Ligases and MicroRNA Signature, for the Development of New Immunotherapeutic Approaches in Glioma
- Heal Italia
- D3 4 Health
- TRIglIFO2 project
- Poc MIMIT Project
- The PROMlSE project
- The 4Immunogenomics project
- Project ERBB2
- Project NANO-COVID-TEST
- Progetto DOMINO – Lazio Innova
- Project GEMMA – Lazio Innova
- Project COMETA
- Exploring the role of Bcl-2 family in the immune surveillance of melanoma: from mechanisms to therapeutic perspectives
- Exploring how endothelin-1/PIEZO axis intersects mechanical forces to fuel PARP inhibitor resistance in ovarian cancer
- The PROGRESS Project
- ULYSSES Project
- VerSiLiB Project
- PRODIGI Project
- LASERBLOOD Project
- BioCIPN Project
The PROGRESS Project

Project Website: PROGRESS – STEP Lazio
Project description

The PROGRESS project was established with the aim of creating an integrated, high-tech facility capable of offering innovative services to support personalized oncology, the development of new pharmacological therapies, and the validation of advanced drug delivery systems. To this end, the project is based on two overarching objectives:
1 (a). The creation of a composite facility—comprising a module for generating and growing Patient-Derived Tumor Organoids (PDTOs) with pre- and post-treatment analysis capabilities, a molecular farming unit for monoclonal antibody (mAb) production, and advanced laboratories for genomic and transcriptomic analysis. The goal is to enable the facility to provide **services tailored to three distinct user groups**: clinicians, pharmaceutical companies, and biotech firms specializing in drug delivery systems.
2. (b) The implementation of process innovations within the project’s core technologies (PDTO culture, pharmacological testing, mAb production, drug delivery), aimed at enhancing the efficacy, reproducibility, and industrial scalability of the services, while incorporating activities with high technological impact that offer potential for patenting.
Purpose
PROGRESS will establish a facility for producing and analyzing tumor organoids, useful for evaluating cancer therapies on *ex vivo* models, as well as new drugs and innovative drug delivery systems (drug carriers).
Results
- Preclinical validation of three highly specialized modular services;
- Introduction of patentable innovations in PDTO culture, mAb production, and drug delivery processes;
- Generation of know-how and technological assets with potential for commercial and industrial exploitation.
Financial Support
PR FESR LAZIO 2021 – 2027
The total grant of the project is 1.902.544,93 euro (CUP: F81B26000070006)
The GRANT assigned to IFO-IRE is 367.905,67 euro (codice CUP IFO-IRE: H53C26000700002)
Principal Investigator: Dr. Giovanni Blandino, Translational Oncology Research Unit of IFO-IRE.
The funding resources are from the public Call "STEP Lazio Sostegno allo Sviluppo e alla fabbricazione delle tecnologie critiche” approved with Determination n. G08307 del 30/06/2025, PR FESR 2021-2027;
Proposal number prot. n. A0896-2025-095281 of 17/07/2025, approved with Determination n. G05594 of 27/04/2026 published on B.U.R. Lazio n. 35 of 30/04/2026.




